DENTSPLY SIRONA Inc.

LSE:0I8F Stock Report

Market Cap: US$3.8b

DENTSPLY SIRONA Valuation

Is 0I8F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0I8F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0I8F ($19.65) is trading below our estimate of fair value ($33.41)

Significantly Below Fair Value: 0I8F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0I8F?

Key metric: As 0I8F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0I8F. This is calculated by dividing 0I8F's market cap by their current revenue.
What is 0I8F's PS Ratio?
PS Ratio1x
SalesUS$3.90b
Market CapUS$3.81b

Price to Sales Ratio vs Peers

How does 0I8F's PS Ratio compare to its peers?

The above table shows the PS ratio for 0I8F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.9x
CTEC ConvaTec Group
2.8x5.7%UK£4.9b
AMS Advanced Medical Solutions Group
3.5x16.8%UK£462.8m
TSTL Tristel
5x10.5%UK£209.8m
SPEC INSPECS Group
0.3x5.5%UK£51.9m
0I8F DENTSPLY SIRONA
1x1.2%US$3.8b

Price-To-Sales vs Peers: 0I8F is good value based on its Price-To-Sales Ratio (1x) compared to the peer average (2.9x).

Price to Sales Ratio vs Industry

How does 0I8F's PS Ratio compare vs other companies in the GB Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
SPEC INSPECS Group
0.3x5.5%US$65.73m
YGEN Yourgene Health
0.6xn/aUS$20.48m
IHC Inspiration Healthcare Group
0.4x13.6%US$17.33m
SUN Surgical Innovations Group
0.4xn/aUS$6.50m
No more companies available in this PS range
0I8F 1.0xIndustry Avg. 3.0xNo. of Companies4PS02.44.87.29.612+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0I8F is good value based on its Price-To-Sales Ratio (1x) compared to the UK Medical Equipment industry average (2.9x).

Price to Sales Ratio vs Fair Ratio

What is 0I8F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0I8F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1x
Fair PS Ratio2x

Price-To-Sales vs Fair Ratio: 0I8F is good value based on its Price-To-Sales Ratio (1x) compared to the estimated Fair Price-To-Sales Ratio (2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0I8F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$19.62
US$24.35
+24.1%
18.4%US$35.00US$19.00n/a13
Nov ’25US$23.51
US$30.15
+28.3%
10.1%US$36.00US$26.00n/a13
Oct ’25US$26.19
US$31.08
+18.7%
9.4%US$36.00US$27.00n/a13
Sep ’25US$25.16
US$31.08
+23.5%
9.4%US$36.00US$27.00n/a13
Aug ’25US$26.88
US$31.65
+17.8%
10.6%US$37.50US$27.00n/a13
Jul ’25US$24.63
US$33.18
+34.7%
11.2%US$38.00US$27.00n/a14
Jun ’25US$27.81
US$33.82
+21.6%
9.8%US$38.00US$27.00n/a14
May ’25US$30.29
US$36.37
+20.1%
10.6%US$42.00US$27.00n/a15
Apr ’25US$33.31
US$36.32
+9.0%
11.0%US$42.00US$27.00n/a14
Mar ’25US$33.49
US$36.32
+8.5%
11.0%US$42.00US$27.00n/a14
Feb ’25US$34.97
US$36.23
+3.6%
11.7%US$42.00US$27.00n/a13
Jan ’25US$35.54
US$34.15
-3.9%
11.8%US$41.00US$27.00n/a13
Dec ’24US$32.57
US$33.92
+4.2%
11.6%US$41.00US$27.00n/a13
Nov ’24US$30.67
US$40.67
+32.6%
14.4%US$51.00US$28.00US$23.5112
Oct ’24US$34.59
US$44.27
+28.0%
7.8%US$51.00US$39.00US$26.1911
Sep ’24US$37.34
US$44.55
+19.3%
7.0%US$51.00US$40.00US$25.1611
Aug ’24US$41.35
US$44.00
+6.4%
7.8%US$51.00US$40.00US$26.8811
Jul ’24US$39.89
US$44.27
+11.0%
7.7%US$51.00US$40.00US$24.6311
Jun ’24US$37.48
US$44.27
+18.1%
7.7%US$51.00US$40.00US$27.8111
May ’24US$42.22
US$40.64
-3.8%
7.8%US$45.00US$36.00US$30.2911
Apr ’24US$38.29
US$39.82
+4.0%
6.9%US$45.00US$36.00US$33.3111
Mar ’24US$37.49
US$39.73
+6.0%
6.7%US$45.00US$36.00US$33.4911
Feb ’24US$37.27
US$35.18
-5.6%
9.0%US$40.00US$29.00US$34.9711
Jan ’24US$31.73
US$34.45
+8.6%
8.9%US$40.00US$29.00US$35.5411
Dec ’23US$29.71
US$34.45
+16.0%
8.9%US$40.00US$29.00US$32.5711
Nov ’23US$30.59
US$40.55
+32.6%
13.4%US$51.00US$33.00US$30.6711

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Centene

US$30.3b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

0HVB

US$60.26

7D

2.1%

1Y

-14.5%

Kooth

UK£64.8m

Provides digital mental health services to children, young people, and adults in the United Kingdom.

KOO

UK£1.78

7D

7.6%

1Y

-40.4%

Enovis

US$2.7b

Operates as a medical technology company focus on developing clinically differentiated solutions worldwide.

0I1B

US$48.46

7D

9.7%

1Y

-3.3%